EXACT Sciences (NASDAQ:EXAS) is set to announce its earnings results after the market closes on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Shares of EXACT Sciences (NASDAQ EXAS) opened at $48.01 on Wednesday. The company has a market capitalization of $5,750.00, a price-to-earnings ratio of -41.75 and a beta of 0.58. The company has a current ratio of 10.34, a quick ratio of 9.98 and a debt-to-equity ratio of 0.01. EXACT Sciences has a 1 year low of $19.54 and a 1 year high of $63.60.
A number of analysts recently commented on EXAS shares. Jefferies Group upped their price objective on EXACT Sciences to $60.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st. Leerink Swann reiterated an “outperform” rating and set a $63.00 price objective (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Benchmark reiterated a “buy” rating and set a $60.00 price objective (up previously from $50.00) on shares of EXACT Sciences in a research report on Tuesday, October 31st. Craig Hallum upped their price objective on EXACT Sciences from $46.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Robert W. Baird upped their price objective on EXACT Sciences from $49.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. Eight equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $52.84.
In other EXACT Sciences news, insider Graham Peter Lidgard sold 45,770 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $58.27, for a total value of $2,667,017.90. Following the completion of the sale, the insider now owns 237,820 shares in the company, valued at $13,857,771.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 630,125 shares of company stock valued at $32,597,655. Company insiders own 4.00% of the company’s stock.
WARNING: “EXACT Sciences (EXAS) to Release Earnings on Thursday” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/21/exact-sciences-exas-to-release-earnings-on-thursday.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.